Highlights

  • RocketDNA has proposed the issue of up to 103,520,582 shares at A$0.0215 per share.
  • Based on the share count and price, the Placement implies about A$2.23 million.
  • Funds will support xBot hardware deployment, software engineering, cyber-security accreditation and working capital.
  • The shares are expected to be issued on 12 October 2026.

RocketDNA Ltd. (ASX:RKT) has lodged an Appendix 3B outlining a proposed strategic private placement of new ordinary shares. The company said the placement was undertaken for expediency and certainty, with funds to support the rollout of its xBot technology.

Placement Details

RocketDNA plans to issue up to 103,520,582 ordinary fully paid shares at A$0.0215 per share, payable in cash. Based on these figures, the placement implies gross proceeds of about A$2.23 million. The proposed Issue Date is 12 October 2026.

All shares are proposed to be issued under the company's additional 10% placement capacity under Listing Rule 7.1A, without security holder approval. The new shares will rank equally with existing shares.

Use of Proceeds

Funds will be directed towards the build-out and deployment of xBot® hardware, along with software engineering and cyber-security accreditation.

The balance will be used for working capital.

Rationale for a Strategic Placement

Explaining why it chose a placement over a pro rata issue or share purchase plan, RocketDNA described it as "a strategic private placement which has been undertaken for expediency and certainty."

No lead manager, broker or underwriter fees were listed in the Appendix 3B. Any on-sale of the new shares within 12 months will rely on a cleansing notice under the Corporations Act.

Key Takeaways

  • RocketDNA plans to raise about A$2.23 million through a strategic placement.
  • The shares will be issued under the company's Listing Rule 7.1A capacity.
  • Funds are focused on xBot hardware deployment and software development.
  • No lead manager or broker fees were listed for the placement.